Related Experiment Video

Updated: Sep 17, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?

Shenao Fu1, Jiayao Ma1, Changjing Cai1

  • 1Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.

Journal of Experimental & Clinical Cancer Research : CR
|July 3, 2025
PubMed

Insights

Targeted therapies for KRAS mutations are advancing, but challenges remain. Understanding how KRAS mutations impact the tumor immune microenvironment is key for developing effective immunotherapies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Targeted therapies for KRAS mutations have evolved, moving beyond the "undruggable" concept.
  • Despite progress, KRAS-targeted therapies face challenges like resistance, efficacy, and toxicity.
  • KRAS mutations significantly alter the tumor immune microenvironment, influencing immunotherapy outcomes.

Purpose of the Study:

  • To review the history and challenges of KRAS-targeted therapy.
  • To summarize the impact of KRAS mutations on the tumor immune microenvironment.
  • To explore potential immunotherapeutic strategies based on KRAS mutation subtypes.

Main Methods:

  • Literature review of KRAS-targeted therapies and their challenges.
  • Analysis of research on KRAS mutations and their effects on the tumor immune microenvironment.
  • Comparative review of immune microenvironments across different KRAS mutation and co-mutation subtypes.

Main Results:

  • KRAS mutations are no longer considered "undruggable" due to recent therapeutic advancements.
  • KRAS mutations profoundly influence the tumor immune microenvironment, presenting immunotherapy opportunities and challenges.
  • Distinct KRAS mutation types and co-mutations lead to varied immune microenvironments, impacting immunotherapy selection.

Conclusions:

  • Alternative treatment modalities are essential due to limitations in current KRAS-targeted therapies.
  • Tailoring immunotherapy based on specific KRAS mutation profiles is crucial for optimizing treatment efficacy.
  • Further research into KRAS mutation-driven immune alterations can guide future cancer immunotherapy development.
Keywords:
CancerImmunotherapyKRASMicroenvironmentTargeted therapy

More Related Videos

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.9K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

705

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K